Drugs / CNTO 6785
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01288196 | Feb → Aug 2011 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01966549 | Nov 2013 → Sep 2015 | chronic obstructive pulmonary disease | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT01909427 | Jun 2013 → Dec 2014 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTO 6785 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288196 ↗ |
| Modality | Monoclonal antibody | “anti-IL-17A monoclonal antibody CNTO 6785” PMID 28753067 ↗ Jul 2017 |
| Route | Intravenous | “30-minute intravenous (IV) (injection into a blood vessel) infusion” NCT01288196 ↗ |
| Target | IL17A | “anti-IL-17A monoclonal antibody CNTO 6785” PMID 28753067 ↗ Jul 2017 |